Pharmaceutical compositions and the treatment of overactive bladder
US10668034B2 · kind B2 · utility
0Cited by
25References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2019 |
| Grant date | Jun 2, 2020 |
| Priority date | — |
| Expiry date | May 31, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/445
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of micturitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.